High-throughput screening of tyrosine kinase inhibitor cardiotoxicity with human induced pluripotent stem cells
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
Tyrosine kinase inhibitors (TKIs), despite their efficacy as anticancer therapeutics, are associated with cardiovascular side effects ranging from induced arrhythmias to heart failure. We used human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs), generated from 11 healthy individuals and 2 patients receiving cancer treatment, to screen U.S. Food and Drug Administration-approved TKIs for cardiotoxicities by measuring alterations in cardiomyocyte viability, contractility, electrophysiology, calcium handling, and signaling. With these data, we generated a "cardiac safety index" to reflect the cardiotoxicities of existing TKIs. TKIs with low cardiac safety indices exhibit cardiotoxicity in patients. We also derived endothelial cells (hiPSC-ECs) and cardiac fibroblasts (hiPSC-CFs) to examine cell type-specific cardiotoxicities. Using high-throughput screening, we determined that vascular endothelial growth factor receptor 2 (VEGFR2)/platelet-derived growth factor receptor (PDGFR)-inhibiting TKIs caused cardiotoxicity in hiPSC-CMs, hiPSC-ECs, and hiPSC-CFs. With phosphoprotein analysis, we determined that VEGFR2/PDGFR-inhibiting TKIs led to a compensatory increase in cardioprotective insulin and insulin-like growth factor (IGF) signaling in hiPSC-CMs. Up-regulating cardioprotective signaling with exogenous insulin or IGF1 improved hiPSC-CM viability during cotreatment with cardiotoxic VEGFR2/PDGFR-inhibiting TKIs. Thus, hiPSC-CMs can be used to screen for cardiovascular toxicities associated with anticancer TKIs, and the results correlate with clinical phenotypes. This approach provides unexpected insights, as illustrated by our finding that toxicity can be alleviated via cardioprotective insulin/IGF signaling.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“they generated a “cardiac safety index” to reflect the safety of existing tyrosine kinase inhibitors [23].”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [23]
The cited source says what the claim attributes to it.
In the citing paper
“Sharma et al., 2017 performed a high-throughput toxicity screen assessing the cardiotoxicity of small molecule tyrosine kinase inhibitors.”
From Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy (2022) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Induction of Pluripotent Stem Cells from Adult Human Fibroblasts by Defined Factors
Takahashi, K., Tanabe, K., Ohnuki, M., Narita, M., Ichisaka, T., Tomoda, K., & Yamanaka, S. (2007) · Cell · doi:10.1016/j.cell.2007.11.019 · Cited by 20,221
Grothey, A., Cutsem, E. V., Sobrero, A., Siena, S., Falcone, A., Ychou, M., Humblet, Y., Bouché, O., Mineur, L., Barone, C., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61900-x · Cited by 2,895
van der Graaf, W. T., Blay, J.-Y., Chawla, S. P., Kim, D.-W., Bui-Nguyen, B., Casali, P. G., Schöffski, P., Aglietta, M., Staddon, A. P., Beppu, Y., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60651-5 · Cited by 2,102
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
Byrd, J. C., Brown, J. R., O'Brien, S., Barrientos, J. C., Kay, N. E., Reddy, N. M., Coutre, S., Tam, C. S., Mulligan, S. P., Jaeger, U., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1400376 · Cited by 1,639
Chemically defined generation of human cardiomyocytes
Burridge, P. W., Matsa, E., Shukla, P., Lin, Z. C., Churko, J. M., Ebert, A. D., Lan, F., Diecke, S., Huber, B., Mordwinkin, N. M., et al. (2014) · Nature Methods · doi:10.1038/nmeth.2999 · Cited by 1,606 · cited 5×
“Chemically defined differentiation of hiPSC-CMs The hiPSCs were differentiated into hiPSC-CMs using a chemically defined protocol and maintained in medium supplemented with human albumin and ascorbic acid (8).”
BackgroundMethodInfluentialSelf-citationDemetri, G. D., Reichardt, P., Kang, Y.-K., Blay, J.-Y., Rutkowski, P., Gelderblom, H., Hohenberger, P., Leahy, M., von Mehren, M., Joensuu, H., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61857-1 · Cited by 1,406
Wilhelm, S. M., Dumas, J., Adnane, L., Lynch, M., Carter, C. A., Schütz, G., Thierauch, K., & Zopf, D. (2011) · International Journal of Cancer · doi:10.1002/ijc.25864 · Cited by 1,355 · cited 1×
“This is reasonable because sorafenib and regorafenib (also known as fluoro-sorafenib) have similar molecular structures (24).”
BackgroundCardiovascular Complications of Cancer Therapy
Yeh, E. T. H., & Bickford, C. L. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2009.02.050 · Cited by 1,275 · cited 1×
“However, some TKIs are linked to severe cardiotoxicities including heart failure, reduced left ventricular ejection fraction, myocardial infarction, or arrhythmias (2, 3).”
BackgroundPatient-Specific Induced Pluripotent Stem-Cell Models for Long-QT Syndrome
Moretti, A., Bellin, M., Welling, A., Jung, C. B., Lam, J. T., Bott-Flügel, L., Dorn, T., Goedel, A., Höhnke, C., Hofmann, F., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908679 · Cited by 1,251
Cited by
Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia
Herrmann, J. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0348-1 · Cited by 747
Czerniecki, S. M., Cruz, N. M., Harder, J. L., Menon, R., Annis, J., Otto, E. A., Gulieva, R. E., Islas, L. V., Kim, Y. K., Tran, L. M., et al. (2018) · Cell Stem Cell · doi:10.1016/j.stem.2018.04.022 · Cited by 465
Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications
Cerneckis, J., Cai, H., & Shi, Y. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01809-0 · Cited by 452
“424 Indeed, adding exogenous insulin or IGF1 improves cardiomyocyte viability in the presence of tyrosine kinase inhibitors.”
BackgroundMetabolic Maturation Media Improve Physiological Function of Human iPSC-Derived Cardiomyocytes
Feyen, D. A. M., McKeithan, W. L., Bruyneel, A. A. N., Spiering, S., Hörmann, L., Ulmer, B., Zhang, H., Briganti, F., Schweizer, M., Hegyi, B., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.107925 · Cited by 400
“The contractility image analysis and physiological parameter calculation were conducted as previously described (Sharma et al., 2017).”
Self-citationHuman iPSC-Derived Cardiomyocytes Are Susceptible to SARS-CoV-2 Infection
Sharma, A., Garcia, G., Wang, Y., Plummer, J. T., Morizono, K., Arumugaswami, V., & Svendsen, C. N. (2020) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100052 · Cited by 318
“HiPSC-CMs can recapitulate cellular phenotypes for cardiovascular diseases including various forms of cardiomyopathy(19,20) and drug-induced cardiotoxicity.(21,22) Notably, hiPSC-CMs have also shown promise as an in vitro model for studying the mechanisms of direct CM viral infection in the context of viral myocarditi…”
BackgroundSelf-citationMulti-lineage human iPSC-derived platforms for disease modeling and drug discovery
Sharma, A., Sances, S., Workman, M. J., & Svendsen, C. N. (2020) · Cell Stem Cell · doi:10.1016/j.stem.2020.02.011 · Cited by 296
“Additionally, chemotherapeutic compounds such as tyrosine kinase inhibitors elicit simultaneous cardiac and endothelial toxicity and, therefore, co-culture could be valuable for assessing drug toxicity (Sharma et al., 2017).”
BackgroundSelf-citationMusunuru, K., Sheikh, F., Gupta, R. M., Houser, S. R., Maher, K. O., Milan, D. J., Terzic, A., & Wu, J. C. (2018) · Circulation: Genomic and Precision Medicine · doi:10.1161/hcg.0000000000000043 · Cited by 229
Self-citationRetinal stem cell transplantation: Balancing safety and potential
Singh, M. S., Park, S. S., Albini, T. A., Canto-Soler, M. V., Klassen, H., MacLaren, R. E., Takahashi, M., Nagiel, A., Schwartz, S. D., & Bharti, K. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2019.100779 · Cited by 225
Deep Learning-Based Prediction of Drug-Induced Cardiotoxicity
Cai, C., Guo, P., Zhou, Y., Zhou, J., Wang, Q., Zhang, F., Fang, J., & Cheng, F. (2019) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.8b00769 · Cited by 217
Activation of PDGF pathway links LMNA mutation to dilated cardiomyopathy
Lee, J., Termglinchan, V., Diecke, S., Itzhaki, I., Lam, C. K., Garg, P., Lau, E., Greenhaw, M., Seeger, T., Wu, H., et al. (2019) · Nature · doi:10.1038/s41586-019-1406-x · Cited by 222
Self-citationHu, D., Linders, A., Yamak, A., Correia, C., Kijlstra, J. D., Garakani, A., Xiao, L., Milan, D. J., van der Meer, P., Serra, M., et al. (2018) · Circulation Research · doi:10.1161/circresaha.118.313249 · Cited by 219
Paik, D. T., Chandy, M., & Wu, J. C. (2020) · Pharmacological Reviews · doi:10.1124/pr.116.013003 · Cited by 216
“…iPSCs have been used to assess whether genetic variants in individual patients are pathogenic or benign (Garg et al., 2018; Ma et al., 2018) and have proven useful in patient-specific drug screening and drug toxicity testing (Burridge et al., 2016; Matsa et al., 2016; Sharma et al., 2017, 2018).”
BackgroundMethodInfluentialSelf-citationCardio-oncology - strategies for management of cancer-therapy related cardiovascular disease
Totzeck, M., Schuler, M., Stuschke, M., Heusch, G., & Rassaf, T. (2019) · International Journal of Cardiology · doi:10.1016/j.ijcard.2019.01.038 · Cited by 206
Kitani, T., Ong, S.-G., Lam, C. K., Rhee, J.-W., Zhang, J. Z., Oikonomopoulos, A., Ma, N., Tian, L., Lee, J., Telli, M. L., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.037357 · Cited by 200
Self-citationApplications of synthetic biology in medical and pharmaceutical fields
Yan, X., Liu, X., Zhao, C., & Chen, G.-Q. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01440-5 · Cited by 179
“Various applications combined with therapeutic chemicals and iPSC cell lines are undergoing high-throughput drug screening and analysis.(80,81) iPSCs are aimed to be used for tissue regeneration and therapy developments.”
BackgroundGintant, G. A., Burridge, P. W., Gepstein, L., Harding, S. E., Herron, T. J., Hong, C. C., Jalife, J., & Wu, J. C. (2019) · Circulation Research · doi:10.1161/res.0000000000000291 · Cited by 215
Self-citationProtze, S. I., Lee, J. H., & Keller, G. M. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.07.010 · Cited by 162
Next generation of heart regenerative therapies: progress and promise of cardiac tissue engineering
Tenreiro, M. F., Louro, A. F., Alves, P. M., & Serra, M. (2021) · npj Regenerative Medicine · doi:10.1038/s41536-021-00140-4 · Cited by 171
Ma, N., Zhang, J. Z., Itzhaki, I., Zhang, S. L., Chen, H., Haddad, F., Kitani, T., Wilson, K. D., Tian, L., Shrestha, R., et al. (2018) · Circulation · doi:10.1161/circulationaha.117.032273 · Cited by 144
Self-citationUse of human induced pluripotent stem cell–derived cardiomyocytes to assess drug cardiotoxicity
Sharma, A., McKeithan, W. L., Serrano, R., Kitani, T., Burridge, P. W., del Álamo, J. C., Mercola, M., & Wu, J. C. (2018) · Nature Protocols · doi:10.1038/s41596-018-0076-8 · Cited by 139
Self-citationMultiscale technologies for treatment of ischemic cardiomyopathy
Mahmoudi, M., Yu, M., Serpooshan, V., Wu, J. C., Langer, R., Lee, R. T., Karp, J. M., & Farokhzad, O. C. (2017) · Nature Nanotechnology · doi:10.1038/nnano.2017.167 · Cited by 147
Self-citationProgress, obstacles, and limitations in the use of stem cells in organ-on-a-chip models
Wnorowski, A., Yang, H., & Wu, J. C. (2019) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.06.001 · Cited by 124
Self-citationCardiovascular Precision Medicine in the Genomics Era
Dainis, A., & Ashley, E. A. (2018) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2018.01.003 · Cited by 136
“iPSC-derived cardiomyocytes have been used to characterize cellular disease phenotypes (65), assist high-throughput drug discovery (66), and investigate cardiovascular metabolism (67), among myriad other applications (68), thus solidifying their critical role in current cardiovascular investigation.”
Magdy, T., Schuldt, A. J. T., Wu, J. C., Bernstein, D., & Burridge, P. W. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-053110 · Cited by 109
Self-citationWnorowski, A. N., Sharma, A., Chen, H., Wu, H., Shao, N., Sayed, N., Liu, C., Countryman, S. M., Stodieck, L., Rubins, K., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.10.006 · Cited by 120
Self-citationStrategies for Improving the Maturity of Human Induced Pluripotent Stem Cell-Derived Cardiomyocytes
Tu, C., Chao, B. S., & Wu, J. C. (2018) · Circulation Research · doi:10.1161/circresaha.118.313472 · Cited by 113
“ity of drugs, such as the widely used chemotherapy reagents doxorubicin(4) and tyrosine kinase inhibitors.(5) Such prediction”
BackgroundSelf-citationToepfer, C. N., Sharma, A., Cicconet, M., Garfinkel, A. C., Mücke, M., Neyazi, M., Willcox, J. A. L., Agarwal, R., Schmid, M., Rao, J., et al. (2019) · Circulation Research · doi:10.1161/circresaha.118.314505 · Cited by 119
“Studies of hiPSC-CMs have already contributed insights into cardiomyocyte biology,(6) heart disease mechanisms,(7,8) and have uncovered off-target cardiotoxic drug effects.(9,10)”
BackgroundMethodSelf-citationHuman Organoids for Predictive Toxicology Research and Drug Development
Matsui, T., & Shinozawa, T. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.767621 · Cited by 109
Fiedler, L. R., Chapman, K., Xie, M., Maifoshie, E., Jenkins, M., Golforoush, P. A., Bellahcene, M., Noseda, M., Faust, D., Jarvis, A., et al. (2019) · Cell Stem Cell · doi:10.1016/j.stem.2019.01.013 · Cited by 102
Lin, Y., Gil, C.-H., & Yöder, M. C. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.117.309962 · Cited by 111
Zheng, P., Li, J., & Kros, J. M. (2017) · Medicinal Research Reviews · doi:10.1002/med.21463 · Cited by 108
Song, M., Xia, W., Tao, Z., Zhu, B., Zhang, W., Liu, C., & Chen, S. (2021) · Drug Delivery · doi:10.1080/10717544.2021.1898703 · Cited by 104
“healthy tissues, and nonspecificity toward cancer cells (Sharma et al., 2017; Nakajima et al., 2020).”
BackgroundWilliams, I. M., & Wu, J. C. (2019) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.119.312265 · Cited by 91
Self-citationvan der Velden, J., Asselbergs, F. W., Bakkers, J., Bátkai, S., Bertrand, L., Bezzina, C. R., Bot, I., Brundel, B. J. J. M., Carrier, L., Chamuleau, S. A. J., et al. (2022) · Cardiovascular Research · doi:10.1093/cvr/cvab370 · Cited by 105
Singh, A. P., Glennon, M. S., Umbarkar, P., Gupte, M., Galindo, C. L., Zhang, Q., Force, T. L., Becker, J. R., & Lal, H. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz006 · Cited by 96
Multiscale drug screening for cardiac fibrosis identifies MD2 as a therapeutic target
Zhang, H., Thai, P. N., Shivnaraine, R. V., Ren, L., Wu, X., Siepe, D. H., Liu, Y., Tu, C., Shin, H. S., Caudal, A., et al. (2024) · Cell · doi:10.1016/j.cell.2024.09.034 · Cited by 102
Self-citationRepurposing drugs to treat cardiovascular disease in the era of precision medicine
Abdelsayed, M., Kort, E. J., Jovinge, S., & Mercola, M. (2022) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00717-6 · Cited by 93
“For example, vascular and cardiomyopathic effects of oncology therapeutics have been modelled in iPSC-CM and zebrafish models 102,103 , establishing the groundwork to explore the chemical basis for the cardiotoxic effects of oncology therapeutics.”
BackgroundSelf-citationAndrysiak, K., Stępniewski, J., & Dulak, J. (2021) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-021-02536-z · Cited by 103
Tocchetti, C. G., Ameri, P., de Boer, R. A., D’Alessandra, Y., Russo, M., Sorriento, D., Ciccarelli, M., Kiss, B., Bertrand, L., Dawson, D. K., et al. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvaa222 · Cited by 100
Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes
Burnett, S. D., Blanchette, A. D., Grimm, F. A., House, J. S., Reif, D. M., Wright, F. A., Chiu, W. A., & Rusyn, I. (2019) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2019.114711 · Cited by 126
“Human iPSC-derived cardiomyocytes have emerged as an attractive organotypic in vitro model for cardiotoxicity testing because they demonstrate biological relevance, high sensitivity and specificity, and consistent reproducibility (Burridge et al., 2016; Blinova et al., 2017; Kawatou et al., 2017; Sharma et al., 2017;…”
BackgroundOikonomopoulos, A., Kitani, T., & Wu, J. C. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.026 · Cited by 95
Self-citationParrotta, E. I., Lucchino, V., Scaramuzzino, L., Scalise, S., & Cuda, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124354 · Cited by 88
“The in vitro high-throughput screening performed on iPSCs-CMs derived from healthy individuals and oncologic patients allowed the identification of two TKIs against the vascular endothelial growth factor (VEGF) and platelet-derived growth factor (PDGF) receptors as a mechanism for induced cardiotoxicity [95].”
BackgroundVEGF Receptor Inhibitor-Induced Hypertension: Emerging Mechanisms and Clinical Implications
Camarda, N. D., Travers, R. J., Yang, V. K., London, C. A., & Jaffe, I. Z. (2022) · Current Oncology Reports · doi:10.1007/s11912-022-01224-0 · Cited by 95
Choi, S. W., Shin, J. S., Park, S., Jung, E., Park, Y.-G., Lee, J., Kim, S. J., Park, H., Lee, J., Park, S., et al. (2020) · Antiviral Research · doi:10.1016/j.antiviral.2020.104955 · Cited by 91
“Most importantly, hPSC-CMs are capable of recapitulating cardiac pathophysiology, rendering them ideal for assessing cardiac safety in preclinical drug screening (Moreno and Pearson, 2013; Sharma et al., 2017).”
BackgroundCardiotoxicity of the BCR-ABL1 tyrosine kinase inhibitors: Emphasis on ponatinib
Singh, A. P., Umbarkar, P., Tousif, S., & Lal, H. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.05.077 · Cited by 85
“Notably, several recent reports have suggested that ponatinib is the most cardiotoxic agent in all FDA approved TKIs ([12, 13].”
BackgroundMethodInfluentialThomas, D., Cunningham, N. J., Shenoy, S., & Wu, J. C. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvab115 · Cited by 90
Self-citationCardiovascular Toxicity Induced by Kinase Inhibitors: Mechanisms and Preclinical Approaches
Lamore, S. D., Kohnken, R. A., Peters, M. F., & Kolaja, K. L. (2019) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.9b00387 · Cited by 82
Human iPSC modeling of heart disease for drug development
Hnatiuk, A. P., Briganti, F., Staudt, D., & Mercola, M. A. (2021) · Cell chemical biology · doi:10.1016/j.chembiol.2021.02.016 · Cited by 82
Self-citationBurnett, S. D., Blanchette, A. D., Chiu, W. A., & Rusyn, I. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1894122 · Cited by 117
Shen, M., Quertermous, T., Fischbein, M. P., & Wu, J. C. (2021) · Circulation Research · doi:10.1161/circresaha.120.318049 · Cited by 80
Self-citationPonatinib Drives Cardiotoxicity by S100A8/A9-NLRP3-IL-1β Mediated Inflammation
Tousif, S., Singh, A. P., Umbarkar, P., Galindo, C. L., Wheeler, N. D., Cora, A. T., Zhang, Q., Prabhu, S. D., & Lal, H. (2023) · Circulation Research · doi:10.1161/circresaha.122.321504 · Cited by 79
van Meer, B. J., Krotenberg, A., Sala, L., Davis, R. P., Eschenhagen, T., Denning, C., Tertoolen, L. G. J., & Mummery, C. L. (2019) · Nature Communications · doi:10.1038/s41467-019-12354-8 · Cited by 73
Wang, H., Wang, Y., Li, J., He, Z., Boswell, S. A., Chung, M., You, F., & Han, S. (2023) · BMC Medicine · doi:10.1186/s12916-023-02838-2 · Cited by 76
“Two previous studies have evaluated over 20 FDA-approved TKIs at a single dose and treatment duration on hiPSCCMs or primary human cardiac cells [9, 37]; we think that we could gain different insights from the previous studies by studying more doses and treatment durations which mimic more variables associated with cl…”
BackgroundThe Evolving Roles of Human iPSC-Derived Cardiomyocytes in Drug Safety and Discovery
Gintant, G. A., Fermini, B., Stockbridge, N., & Strauss, D. G. (2017) · Cell stem cell · doi:10.1016/j.stem.2017.06.005 · Cited by 76
“…toxicity assessments that include multiple functional, morphological, and ‘‘omic’’ approaches, such as biomarkers of cardiac injury, indicators of mitochondrial function, and transcriptomics (Clements et al., 2015; Sharma et al., 2017) to move beyond the electrophysiologic focus of CiPA.”
BackgroundCRISPR/Cas9‐Mediated Fluorescent Tagging of Endogenous Proteins in Human Pluripotent Stem Cells
Sharma, A., Toepfer, C. N., Ward, T. L., Wasson, L. K., Agarwal, R., Conner, D. A., Hu, J. H., & Seidman, C. E. (2018) · Current Protocols in Human Genetics · doi:10.1002/cphg.52 · Cited by 82
“…Library (wileyonlinelibrary.com). doi: 10.1002/cphg.52 Copyright C© 2018 John Wiley & Sons, Inc. iPS Cell Models 21.11.1 Supplement 96 beating hiPSC-derived cardiomyocytes have recapitulated toxicities that are clinically associated with certain chemotherapeutic compounds (Sharma et al., 2017).”
BackgroundInfluentialSelf-citationHuman Engineered Heart Tissue Models for Disease Modeling and Drug Discovery
Tani, H., & Tohyama, S. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.855763 · Cited by 83
Workshop Report: FDA Workshop on Improving Cardiotoxicity Assessment With Human-Relevant Platforms
Pang, L., Sager, P., Yang, X., Shi, H., Sannajust, F., Brock, M., Wu, J. C., Abi-Gerges, N., Lyn-Cook, B., Berridge, B. R., et al. (2019) · Circulation Research · doi:10.1161/circresaha.119.315378 · Cited by 73
Self-citationFeyen, D. A. M., Perea‐Gil, I., Maas, R. G. C., Harakaľová, M., Gavidia, A. A., Ataam, J. A., Wu, T.-H., Vink, A., Pei, J., Vadgama, N., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.049844 · Cited by 76
Self-citationA human population-based organotypic in vitro model for cardiotoxicity screening
Grimm, F. A. (2018) · ALTEX · doi:10.14573/altex.1805301 · Cited by 109
“We sought to demonstrate this approach using iPSC-derived cardiomyocytes, which have emerged as a particularly attractive and valuable in vitro model for cardiotoxicity testing (Blinova et al., 2017; Strauss et al., 2017; Burridge et al., 2016; Sharma et al., 2017; Kawatou et al., 2017).”
From engineered heart tissue to cardiac organoid
Cho, J., Lee, H., Rah, W., Chang, H., & Yoon, Y. (2022) · Theranostics · doi:10.7150/thno.67661 · Cited by 74
“Cardiac disease models were investigated with 2D-cultured hiPSC-CMs carrying genetic mutation(s) or induced pathological cardiac conditions [85-87].”
MethodGrafton, F., Ho, J. J., Ranjbarvaziri, S., Farshidfar, F., Budan, A., Steltzer, S. S., Maddah, M., Loewke, K. E., Green, K., Patel, S. D., et al. (2021) · eLife · doi:10.7554/elife.68714 · Cited by 75
Baldassarre, A. D., Cimetta, E., Bollini, S., Gaggi, G., & Ghinassi, B. (2018) · Cells · doi:10.3390/cells7060048 · Cited by 78
“On the other hand, the hiPSCs represent a renewable cell source of CMs and overcome species differences present in animal models allowing a human-specific assessment of drug-induced contractility changes: expressing human cardiac ion channel, hiPSC-CMs respond to major channel blockers [132] and can also be useful to…”
BackgroundMethodiPSC Modeling of RBM20-Deficient DCM Identifies Upregulation of RBM20 as a Therapeutic Strategy
Briganti, F., Sun, H., Wei, W., Wu, J., Zhu, C., Liss, M., Karakikes, I., Rego, S., Cipriano, A., Snyder, M., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108117 · Cited by 68
“Contractility is quantified as the relative change in area of the beating cells, given by the divergence of the measured deformation field, and reported as the peak divergence amplitude (Serrano et al., 2018; Sharma et al., 2017).”
Self-citationFindley, A. S., Monziani, A., Richards, A. L., Rhodes, K., Ward, M. C., Kalita, C. A., Alazizi, A., Pazokitoroudi, A., Sankararaman, S., Wen, X., et al. (2021) · eLife · doi:10.7554/elife.67077 · Cited by 74
Harnessing organs-on-a-chip to model tissue regeneration
Tavakol, D. N., Fleischer, S., & Vunjak-Novakovic, G. (2021) · Cell Stem Cell · doi:10.1016/j.stem.2021.05.008 · Cited by 63
Wang, H., Sheehan, R. P., Palmer, A. C., Everley, R. A., Boswell, S. A., Ron‐Harel, N., Ringel, A. E., Holton, K. M., Jacobson, C. A., Erickson, A. R., et al. (2019) · Cell Systems · doi:10.1016/j.cels.2019.03.009 · Cited by 71
Utility of iPSC-Derived Cells for Disease Modeling, Drug Development, and Cell Therapy
Nicholson, M. W., Ting, C.-Y., Chan, D. Z. H., Cheng, Y.-C., Lee, Y.-C., Hsu, C.-C., Huang, C.-Y., & Hsieh, P. C. H. (2022) · Cells · doi:10.3390/cells11111853 · Cited by 65
“Sharma et al., 2017 performed a high-throughput toxicity screen assessing the cardiotoxicity of small molecule tyrosine kinase inhibitors.”
Backgroundvan Mil, A., Balk, G. M., Neef, K., Buikema, J. W., Asselbergs, F. W., Wu, S. M., Doevendans, P. A., & Sluijter, J. P. G. (2018) · Cardiovascular Research · doi:10.1093/cvr/cvy208 · Cited by 65
“also been used to screen for cardiovascular toxicities associated with anticancer tyrosine kinase inhibitors.(191) Importantly, the results correlated”
BackgroundSelf-citationAbadi, P. P. S. S., Garbern, J. C., Behzadi, S., Hill, M. J., Tresback, J. S., Heydari, T., Ejtehadi, M. R., Ahmed, N., Copley, E., Aghaverdi, H., et al. (2018) · Advanced Functional Materials · doi:10.1002/adfm.201707378 · Cited by 68
Prasad, M., Kumar, R., Buragohain, L., Kumari, A., & Ghosh, M. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.696668 · Cited by 63
“Analysis of cell viability, apoptosis, injury marker LDH, cardiomyositis indicators such as cardiac troponin T, α-actinin, and CD45/CD14/CD31, ROS generation, altered contractile or ion channel function, and calcium signaling can be carried out as potential biomarkers for NP-induced cardiotoxicity (Doherty et al., 201…”
BackgroundInfluentialVascular toxicity associated with anti-angiogenic drugs
Neves, K. B., Montezano, A. C. I., Lang, N. N., & Touyz, R. M. (2020) · Clinical Science · doi:10.1042/cs20200308 · Cited by 64
Gao, F., Xu, T., Zang, F., Luo, Y., & Pan, D. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s469331 · Cited by 65
The HER2 inhibitor lapatinib potentiates doxorubicin-induced cardiotoxicity through iNOS signaling
Hsu, W.-T., Huang, C., Yen, C. Y. T., Cheng, A., & Hsieh, P. C. H. (2018) · Theranostics · doi:10.7150/thno.23207 · Cited by 58
“In line with a previous study which examined cytotoxicity after 72 h of LAP treatment in five healthy control hiPSC-CM lines [19], LAP alone was not highly cytotoxic in hPSC-CMs at concentrations of 0.”
BackgroundMethodModelling cadmium‐induced cardiotoxicity using human pluripotent stem cell‐derived cardiomyocytes
Shen, J., Wang, X., Zhou, D., Li, T., Tang, L. F. P., Gong, T., Su, J., & Liang, P. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13702 · Cited by 59
“Several studies have demonstrated the reliability of hPSC-CMs to study drug-induced cardiotoxicity in a dish, which encourages us to investigate the CIC using hPSC-CMs.(36-44) In this study, we utilized hPSC-CM as a unique platform to investigate the molecular mechanisms of CIC.”
MethodHeart Failure and Cancer: Mechanisms of Old and New Cardiotoxic Drugs in Cancer Patients
Cuomo, A., Rodolico, A., Galdieri, A., Russo, M., Campi, G., Franco, R., Bruno, D., Aran, L., Carannante, A., Attanasio, U., et al. (2019) · Cardiac failure review · doi:10.15420/cfr.2018.32.2 · Cited by 58
“toxicities of current and novel drugs, in clinical as well as in basic research also considering that these drugs are often combined, thus increasing their cardiotoxic potential.(99,109)”
BackgroundCai, C., Fang, J., Guo, P., Wang, Q., Hong, H., Moslehi, J. J., & Cheng, F. (2018) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.7b00641 · Cited by 52
“Parameter αi is trained via maximizing the Lagrangian expression using equations (5) and (6).”
MethodSelf-citationIbrutinib Displays Atrial-Specific Toxicity in Human Stem Cell-Derived Cardiomyocytes
Shafaattalab, S., Lin, E. C., Christidi, E., Huang, H., Nartiss, Y., Garcia, A., Lee, J., Protze, S. I., Keller, G. M., Brunham, L. R., et al. (2019) · Stem Cell Reports · doi:10.1016/j.stemcr.2019.03.011 · Cited by 56
“positive control for ventricular toxicity in this study (Sharma et al., 2017).”
BackgroundInfluentialModeling trastuzumab-related cardiotoxicity in vitro using human stem cell-derived cardiomyocytes
Kurokawa, Y. K., Shang, M. R., Yin, R. T., & George, S. C. (2018) · Toxicology Letters · doi:10.1016/j.toxlet.2018.01.001 · Cited by 55
Personalized medicine in cardio-oncology: the role of induced pluripotent stem cell
Sayed, N., Ameen, M., & Wu, J. C. (2019) · Cardiovascular Research · doi:10.1093/cvr/cvz024 · Cited by 51
Self-citationMcKeithan, W. L., Feyen, D. A. M., Bruyneel, A. A. N., Okolotowicz, K. J., Ryan, D. A., Sampson, K. J., Potet, F., Savchenko, A., Gómez-Galeno, J., Vu, M., et al. (2020) · Cell stem cell · doi:10.1016/j.stem.2020.08.003 · Cited by 50
“Precedents include predicting proarrhythmic and cardiotoxic responses to drugs and the discovery of small molecule probes of diabetic cardiomyopathy and ischemic heart disease (Blinova et al., 2018; Drawnel et al., 2014; Fiedler et al., 2019; Sharma et al., 2017).”
BackgroundSelf-citationNetwork integration and modelling of dynamic drug responses at multi-omics levels
Selevsek, N., Caiment, F., Nudischer, R., Gmuender, H., Agarkova, I., Atkinson, F. L., Bachmann, I., Baier, V., Barel, G., Bauer, C., et al. (2020) · Communications Biology · doi:10.1038/s42003-020-01302-8 · Cited by 55
Multifunctional Conductive Biomaterials as Promising Platforms for Cardiac Tissue Engineering
Mousavi, A., Vahdat, S., Baheiraei, N., Razavi, M., Norahan, M. H., & Baharvand, H. (2020) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.0c01422 · Cited by 54
Blanchette, A. D., Grimm, F. A., Dalaijamts, C., Hsieh, N., Ferguson, K., Luo, Y., Rusyn, I., & Chiu, W. A. (2018) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.1259 · Cited by 87
“The ability to generate cells from individual donors that replicate patientspecific congenital(17) and diseasespecific(18) phenotypes is an exciting development that promises to enable personalized drug safety evaluation, an approach that has recently been tested in dozens of human induced pluripotent stem cell (iPSC)…”
BackgroundRecent progress of iPSC technology in cardiac diseases
Funakoshi, S., & Yoshida, Y. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03172-3 · Cited by 52
Functional isolation, culture and cryopreservation of adult human primary cardiomyocytes
Zhou, B., Shi, X., Tang, X., Zhao, Q., Wang, L., Yao, F., Hou, Y., Wang, X., Feng, W., Wang, L., et al. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01044-5 · Cited by 46
“Finally, erlotinib, axitinib, trametinib, cabozantinib, mirdametinib, and pazopanib were experimentally and clinically proven to be cardiac safe.(44,50,56) Consistently, these drugs all had very large IC50 values (well above 100 μM) (Fig.”
BackgroundSchwach, V., Slaats, R. H., & Passier, R. C. (2020) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2020.00050 · Cited by 48
“Different TKis show cell type specific cytotoxicity, either in hPSC-derived cardiomyocytes, endothelial cells and fibroblasts or hPSCs, suggesting that TKis differently affect cardiovascular and non-cardiovascular cell types (99).”
BackgroundYang, X., & Papoian, T. (2018) · Journal of Applied Toxicology · doi:10.1002/jat.3611 · Cited by 48
“content screening has shown its ability to distinguish subtle mechanistic differences among different drugs (Doherty et al., 2013; Sharma et al., 2017).”
BackgroundMethodInfluentialClinical trials in-a-dish for cardiovascular medicine
Wu, X., Swanson, K., Yıldırım, Z., Liu, W., Liao, R., & Wu, J. C. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae519 · Cited by 47
Self-citationHoes, M. F., Bömer, N., & van der Meer, P. (2018) · Stem Cells Translational Medicine · doi:10.1002/sctm.18-0052 · Cited by 48
Kennedy, C. C., Brown, E., Abutaleb, N. O., & Truskey, G. A. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.625016 · Cited by 46
“iPSCECs have been used to evaluate the toxicity of chemotherapeutic compounds such as tyrosine kinase inhibitors, which elicit cardiac and endothelial toxicity (57, 115).”
MethodGu, M., Donato, M., Guo, M., Wary, N. K., Miao, Y., Mao, S., Saito, T., Otsuki, S., Wang, L., Harper, R. L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aba6480 · Cited by 47
Thomas, D., Shenoy, S., & Sayed, N. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.607364 · Cited by 39
“One of the first large-scale studies looking at TKI-induced cardiotoxicity tested 21 FDA approved TKIs on iPSC-CMs derived from 11 healthy and two cancer patients on a highthroughput platform (Sharma et al., 2017).”
BackgroundSelf-citationVascularised cardiac spheroids-on-a-chip for testing the toxicity of therapeutics
Ciò, S. D., Marhuenda, E., Haddrick, M., & Gautrot, J. E. (2024) · Scientific Reports · doi:10.1038/s41598-024-53678-w · Cited by 42
da Rocha, A. M., Creech, J., Thonn, E., Mironov, S. V., & Herron, T. J. (2019) · Toxicological Sciences · doi:10.1093/toxsci/kfz235 · Cited by 42
“The use of hiPSC-CMs in the drug discovery space for derisking candidate drugs for proarrhythmia and cardiotoxicity is continuously gaining ground (Authier et al., 2017; Sharma et al., 2017).”
MethodAnthracycline Toxicity: Light at the End of the Tunnel?
Cejas, R. B., Petrykey, K., Sapkota, Y., & Burridge, P. W. (2023) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022823-035521 · Cited by 41
Self-citationDeconvoluting Kinase Inhibitor Induced Cardiotoxicity
Lamore, S. D., Ahlberg, E., Boyer, S. K., Lamb, M. L., Hortigon-Vinagre, M. P., Rodriguez, V., Smith, G. L., Sagemark, J., Carlsson, L., Bates, S. M., et al. (2017) · Toxicological Sciences · doi:10.1093/toxsci/kfx082 · Cited by 42
“Another widely recognized observation is that the overwhelming majority of SMKI with clinical cardiotoxicity are tyrosine kinases inhibitors, thereby raising the possibility that promiscuity within the tyrosine kinase group may be predictive (Kruse et al., 2012; Sharma et al., 2017).”
BackgroundPonatinib: An update on its drug targets, therapeutic potential and safety
Gao, Y., Ding, Y., Tai, X., Zhang, C., & Wang, D. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188949 · Cited by 39
Strengthening cardiac therapy pipelines using human pluripotent stem cell-derived cardiomyocytes
Raniga, K., Nasir, A., Vo, N. T. N., Vaidyanathan, R., Dickerson, S., Hilcove, S. A., Mosqueira, D., Mirams, G. R., Clements, P., Hicks, R., et al. (2024) · Cell stem cell · doi:10.1016/j.stem.2024.01.007 · Cited by 41
Subtype-specific cardiomyocytes for precision medicine: Where are we now?
Zhao, M., Shao, N., & Garg, V. (2020) · Stem Cells · doi:10.1002/stem.3178 · Cited by 41
“genetic variance responsible for cardiac toxicity may be inferred for clinical references [15, 16].”
BackgroundRen, L. M., Zhou, X., Nasiri, R., Fang, J., Jiang, X., Wang, C., Qu, M., Ling, H., Chen, Y., Xue, Y., et al. (2020) · Small Methods · doi:10.1002/smtd.202000438 · Cited by 43
Metadata
- Authors
- Sharma, A., Burridge, P. W., McKeithan, W. L., Serrano, R., Shukla, P., Sayed, N., Churko, J. M., Kitani, T., Wu, H., Holmström, A., Matsa, E., Zhang, Y., Kumar, A., Fan, A. C., del Álamo, J. C., Wu, S. M., Moslehi, J. J., Mercola, M., & Wu, J. C.
- Affiliations
- Stanford Medicine (US)
- Northwestern University (US)
- Sanford Burnham Prebys Medical Discovery Institute (US)
- University of California San Diego (US)
- Department of Mechanical and Aerospace Engineering, University of California, San Diego, La Jolla, CA 92092, USA.
- Vanderbilt-Ingram Cancer Center (US)
- Corresponding author
- Sharma, Arun
- Burridge, Paul W.
- Wu, Joseph C.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2017-02-15
- Volume
- 9
- Issue
- 377
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5409837
- OpenAlex
- W2587938050
- Cited by
- 404
- References
- 49
- Citations by year
- 2026: 16 · 2025: 29 · 2024: 55 · 2023: 34 · 2022: 41 · 2021: 50 · 2020: 56 · 2019: 52 · 2018: 47 · 2017: 23
- FWCI
- 37.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- National Institutes of Health (award280979)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Chemotherapy-induced cardiotoxicity and mitigation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Pluripotent Stem Cells Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Keywords
- tyrosine kinase inhibitors, cardiotoxicity, human induced pluripotent stem cell-derived cardiomyocytes, high-throughput screening, VEGFR-2 inhibitors, PDGFR inhibitors, endothelial cells, cardiac fibroblasts, insulin signaling, IGF-1 signaling, cardioprotection
- MeSH terms
- Fibroblasts, Humans, Insulin, Insulin-Like Growth Factor I, Models, Biological, Phosphorylation, Sarcomeres, Signal Transduction, Biomarkers, Myocytes, Cardiac, Vascular Endothelial Growth Factor Receptor-2, Protein Kinase Inhibitors, Induced Pluripotent Stem Cells, High-Throughput Screening Assays, Cardiotoxicity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.